Filing Details
- Accession Number:
- 0001209191-20-009652
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-02-14 16:22:59
- Reporting Period:
- 2020-02-13
- Accepted Time:
- 2020-02-14 16:22:59
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1595893 | Turning Point Therapeutics Inc. | TPTX | Pharmaceutical Preparations (2834) | 463826166 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1772259 | Jean Jingrong Cui | C/O Turning Point Therapeutics, Inc. 10628 Science Center Drive, Ste. 200 San Diego CA 92121 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Disposition | 2020-02-13 | 200 | $59.83 | 792,519 | No | 4 | S | Indirect | By spouse |
Common Stock | Disposition | 2020-02-13 | 2,400 | $60.70 | 790,119 | No | 4 | S | Indirect | By spouse |
Common Stock | Disposition | 2020-02-13 | 8,800 | $62.18 | 781,319 | No | 4 | S | Indirect | By spouse |
Common Stock | Disposition | 2020-02-13 | 100 | $63.07 | 781,219 | No | 4 | S | Indirect | By spouse |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | S | Indirect | By spouse |
No | 4 | S | Indirect | By spouse |
No | 4 | S | Indirect | By spouse |
No | 4 | S | Indirect | By spouse |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Common Stock | 1,301,298 | Direct |
Footnotes
- Reported transaction occurred pursuant to Rule 10b5-1 Plan adopted by Yishan (Peter) Li.
- The weighted average sale price for the transaction reported was $59.83, and the range of prices were between $59.46 and $60.20. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- The weighted average sale price for the transaction reported was $60.70, and the range of prices were between $60.47 and $61.45. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
- The weighted average sale price for the transaction reported was $62.18, and the range of prices were between $61.79 and $62.75. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.